Related Experiment Videos
Effect of magnesium valproate on amygdala-kindled seizures in the rat: comparison with sodium valproate
R Pallini1, M Palestini, L Lauretti
1Istituto di Neurochirurgia, Facoltà di Medicina e Chirurgia, Università Cattolica, Rome, Italy.
Abstract:
The anticonvulsant activity of a salt of valproic acid (VA), magnesium valproate (MgV), was assessed against amygdala-kindled seizures in rats. The anti-epileptic power of MgV was compared with that of sodium valproate (NaV). Kindling was obtained by delivering daily to one of the amygdala a 2 s train of monophasic square-wave pulses (1 ms, 60 c.p.s., 100-130 microA) via chronically implanted electrodes. Magnesium valproate and NaV were tested once kindling was stabilized and the post-kindling threshold for generalized convulsions was determined. The drugs were administered intraperitoneally in doses ranging from 25 to 200 mg/kg. The injection/test interval was 30 min. Each animal received a single dose every 24 h. Magnesium valproate exhibited an anticonvulsant activity qualitatively and quantitatively similar to that of NaV. Statistically significant differences were not found between the two drugs with respect to the reduction of seizure severity and afterdischarge (AD) duration. The calculated ED50's were 94.58 and 97.41 mg/kg for the suppression of generalized seizures, 176.96 and 129.26 mg/kg for the suppression of partial seizures, 275.96 and 224.13 mg/kg for the suppression of the local AD in the MgV and NaV treated groups, respectively.
Insights
Magnesium valproate (MgV) demonstrates anticonvulsant effects comparable to sodium valproate (NaV) in rats with amygdala-kindled seizures. Both compounds effectively reduced seizure severity and afterdischarge duration, indicating similar anti-epileptic potential.
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Epilepsy is a neurological disorder characterized by recurrent seizures.
- Valproic acid (VA) is a widely used anti-epileptic drug.
- Investigating novel salt forms of established drugs can offer therapeutic advantages.
Purpose of the Study:
- To evaluate the anticonvulsant activity of magnesium valproate (MgV), a salt of valproic acid.
- To compare the efficacy of MgV with sodium valproate (NaV) in an established animal model of epilepsy.
- To determine the dose-response relationship and potency of MgV and NaV.
Main Methods:
- Amygdala-kindled seizures were induced in rats using electrical stimulation.
- Magnesium valproate (MgV) and sodium valproate (NaV) were administered intraperitoneally at various doses (25-200 mg/kg).
- Seizure severity, afterdischarge (AD) duration, and generalized convulsion thresholds were measured 30 minutes post-injection.
Main Results:
- Magnesium valproate (MgV) exhibited anticonvulsant activity similar to sodium valproate (NaV).
- No statistically significant differences were observed between MgV and NaV in reducing seizure severity or AD duration.
- Calculated ED50 values for seizure suppression were comparable between MgV and NaV, with slight variations in potency for different seizure parameters.
Conclusions:
- Magnesium valproate (MgV) possesses comparable anticonvulsant efficacy to sodium valproate (NaV).
- MgV represents a potentially viable alternative anti-epileptic agent.
- Further research may explore the pharmacokinetic and safety profiles of MgV.